Amedeo Smart

Free Medical Literature Service




  Free Subscription

Articles published in
    June 2021
  1. RAU M, Thiele K, Korbinian Hartmann NU, Mollmann J, et al
    Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study.
    Atherosclerosis. 2021;330:8-13.
    >> Share

  2. CHO Y, Jeong Y, Seo DH, Ahn SH, et al
    Use of statin for the primary prevention of cardiovascular outcomes in elderly patients: A propensity-matched cohort study.
    Atherosclerosis. 2021;328:92-99.
    >> Share

    May 2021
  3. AVERNA M, Banach M, Bruckert E, Drexel H, et al
    Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force.
    Atherosclerosis. 2021;325:99-109.
    >> Share

  4. HEIDEMANN BE, Wolters FJ, Kavousi M, Gruppen EG, et al
    Adiposity and the development of dyslipidemia in APOE epsilon2 homozygous subjects: A longitudinal analysis in two population-based cohorts.
    Atherosclerosis. 2021;325:57-62.
    >> Share

  5. MA F, Darabi M, Lhomme M, Tubeuf E, et al
    Phospholipid transfer to high-density lipoprotein (HDL) upon triglyceride lipolysis is directly correlated with HDL-cholesterol levels and is not associated with cardiovascular risk.
    Atherosclerosis. 2021;324:1-8.
    >> Share

    March 2021
  6. LAMINA C, Kronenberg F
    The causal association of bilirubin with cardiovascular disease: Are there still any questions?
    Atherosclerosis. 2021;320:92-94.
    >> Share

    February 2021
  7. KANEKO H, Itoh H, Kiriyama H, Kamon T, et al
    Fasting plasma glucose and subsequent cardiovascular disease among young adults: Analysis of a nationwide epidemiological database.
    Atherosclerosis. 2021;319:35-41.
    >> Share

    December 2020
  8. HOU L, Li H, Si S, Yu Y, et al
    Exploring the causal pathway from bilirubin to CVD and diabetes in the UK biobank cohort study: Observational findings and Mendelian randomization studies.
    Atherosclerosis. 2020 Dec 8. pii: S0021-9150(20)31566.
    >> Share

    October 2020
  9. NING X, Ding N, Ballew SH, Hicks CW, et al
    Diabetes, its duration, and the long-term risk of abdominal aortic aneurysm: The Atherosclerosis Risk in Communities (ARIC) Study.
    Atherosclerosis. 2020;313:137-143.
    >> Share

    August 2020
  10. SHROFF GR, Sanchez OA, Miedema MD, Kramer H, et al
    Coronary artery calcium progresses rapidly and discriminates incident cardiovascular events in chronic kidney disease regardless of diabetes: The Multi-Ethnic Study of Atherosclerosis (MESA).
    Atherosclerosis. 2020;310:75-82.
    >> Share

    July 2020
  11. AL-MALLAH MH, Hyafil F, Santulli G
    No pleotropic effects of linagliptin on atherosclerotic plaques: Case closed.
    Atherosclerosis. 2020;305:61-63.
    >> Share

    June 2020
  12. SEO DH, Lee YH, Suh YJ, Ahn SH, et al
    Low muscle mass is associated with carotid atherosclerosis in patients with type 2 diabetes.
    Atherosclerosis. 2020;305:19-25.
    >> Share

    April 2020
  13. VIRTA J, Hellberg S, Liljenback H, Stahle M, et al
    Effects of dipeptidyl peptidase 4 inhibition on inflammation in atherosclerosis: A (18)F-fluorodeoxyglucose study of a mouse model of atherosclerosis and type 2 diabetes.
    Atherosclerosis. 2020 Apr 10. pii: S0021-9150(20)30194.
    >> Share

  14. BJERRE M, Hilden J, Winkel P, Jensen GB, et al
    Serum osteoprotegerin as a long-term predictor for patients with stable coronary artery disease and its association with diabetes and statin treatment: A CLARICOR trial 10-year follow-up substudy.
    Atherosclerosis. 2020;301:8-14.
    >> Share

  15. LAUCEVICIUS A, Rinkuniene E, Petrulioniene Z, Ryliskyte L, et al
    Trends in cardiovascular risk factor prevalence among Lithuanian middle-aged adults between 2009 and 2018.
    Atherosclerosis. 2020;299:9-14.
    >> Share

    March 2020
  16. LI B, Luo YR, Tian F, Chen YD, et al
    Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes.
    Atherosclerosis. 2020;300:10-18.
    >> Share

  17. YAO Y, Zhu H, Zhu L, Fang Z, et al
    A comprehensive contribution of genetic variations of the insulin-like growth factor 1 signalling pathway to stroke susceptibility.
    Atherosclerosis. 2020;296:59-65.
    >> Share

  18. ADINOLFI LE, Petta S, Fracanzani AL, Coppola C, et al
    Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study.
    Atherosclerosis. 2020;296:40-47.
    >> Share

  19. LESKELA RL, Torvinen A, Rissanen TT, Virtanen V, et al
    Outcomes of lipid control in secondary prevention of coronary artery disease in Finland: A 24-month follow-up after acute coronary syndrome.
    Atherosclerosis. 2020;296:4-10.
    >> Share

  20. LUNDE NN, Gregersen I, Ueland T, Shetelig C, et al
    Legumain is upregulated in acute cardiovascular events and associated with improved outcome - potentially related to anti-inflammatory effects on macrophages.
    Atherosclerosis. 2020;296:74-82.
    >> Share

    February 2020
  21. HAFNER J, Zierfuss B, Schernthaner GH, Schmidt-Erfurth U, et al
    From the eye into the foot?
    Atherosclerosis. 2020;294:41-43.
    >> Share

    January 2020
  22. CHIU YW, Wu CS, Chen PC, Wei YC, et al
    Risk of acute mesenteric ischemia in patients with diabetes: A population-based cohort study in Taiwan.
    Atherosclerosis. 2020;296:18-24.
    >> Share

  23. CHICHAREON P, Modolo R, Kogame N, Takahashi K, et al
    Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study.
    Atherosclerosis. 2020;295:45-53.
    >> Share

    November 2019
  24. RAMIN-MANGATA S, Wargny M, Pichelin M, Le May C, et al
    Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes.
    Atherosclerosis. 2019;293:49-56.
    >> Share

    October 2019
  25. CATAN A, Turpin C, Diotel N, Patche J, et al
    Aging and glycation promote erythrocyte phagocytosis by human endothelial cells: Potential impact in atherothrombosis under diabetic conditions.
    Atherosclerosis. 2019;291:87-98.
    >> Share

    September 2019
  26. REIJRINK M, de Boer SA, Spoor DS, Lefrandt JD, et al
    Visceral adipose tissue volume is associated with premature atherosclerosis in early type 2 diabetes mellitus independent of traditional risk factors.
    Atherosclerosis. 2019;290:87-93.
    >> Share

    August 2019
  27. WEI W, Li XX, Xu M
    Inhibition of vascular neointima hyperplasia by FGF21 associated with FGFR1/Syk/NLRP3 inflammasome pathway in diabetic mice.
    Atherosclerosis. 2019;289:132-142.
    >> Share

    July 2019
  28. MORELLI MB, Wang X, Santulli G
    Functional role of gut microbiota and PCSK9 in the pathogenesis of diabetes mellitus and cardiovascular disease.
    Atherosclerosis. 2019 Jul 30. pii: S0021-9150(19)31425.
    >> Share

  29. KABOOTARI M, Hasheminia M, Guity K, Ramezankhani A, et al
    Gestational diabetes mellitus in mothers and long term cardiovascular disease in both parents: Results of over a decade follow-up of the Iranian population.
    Atherosclerosis. 2019;288:94-100.
    >> Share

  30. BARCHUK M, Schreier L, Lopez G, Cevey A, et al
    Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 and angiopoietin-like protein 4 are associated with the increase of lipoprotein lipase activity in epicardial adipose tissue from diabetic patients.
    Atherosclerosis. 2019;288:51-59.
    >> Share

  31. ANHOLM C, Kumarathurai P, Pedersen LR, Samkani A, et al
    Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
    Atherosclerosis. 2019;288:60-66.
    >> Share

    June 2019
  32. QIU S, Cai X, Liu J, Yang B, et al
    Association between circulating cell adhesion molecules and risk of type 2 diabetes: A meta-analysis.
    Atherosclerosis. 2019;287:147-154.
    >> Share

    May 2019
  33. DE SILVA GS, Desai K, Darwech M, Naim U, et al
    Circulating serum fatty acid synthase is elevated in patients with diabetes and carotid artery stenosis and is LDL-associated.
    Atherosclerosis. 2019;287:38-45.
    >> Share

  34. KOWALL B, Stang A
    Reply to: "Methodological issues regarding "Decline in ankle-brachial index is stronger in poorly than in well controlled diabetes: Results from the Heinz Nixdorf Recall cohort study"".
    Atherosclerosis. 2019 May 4. pii: S0021-9150(19)30401.
    >> Share

    April 2019
    Methodological issues regarding "Decline in ankle-brachial index is stronger in poorly than in well controlled diabetes: Results from the Heinz Nixdorf Recall cohort study".
    Atherosclerosis. 2019 Apr 17. pii: S0021-9150(19)30382.
    >> Share

  36. CHEN Y, Dong J, Zhang X, Chen X, et al
    Evacetrapib reduces prebeta-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes.
    Atherosclerosis. 2019;285:147-152.
    >> Share

  37. RAO AD, Vaz CL, Williams KJ
    Accelerated atherosclerotic cardiovascular risk in type 1 diabetes mellitus: Time for a new idea?
    Atherosclerosis. 2019 Apr 14. pii: S0021-9150(19)30362.
    >> Share

    March 2019
  38. SCHERNTHANER GH, Rami-Merhar B, Zierfuss B
    Gestational diabetes and maternal obesity suggestively priming children's premature atherosclerosis: Is it the mother fault?
    Atherosclerosis. 2019 Mar 4. pii: S0021-9150(19)30115.
    >> Share

  39. HAGENSEN MK, Mortensen MB, Kjolby M, Palmfeldt J, et al
    Increased retention of LDL from type 1 diabetic patients in atherosclerosis-prone areas of the murine arterial wall.
    Atherosclerosis. 2019 Mar 4. pii: S0021-9150(19)30114.
    >> Share

  40. KOWALL B, Erbel R, Moebus S, Lehmann N, et al
    Decline in ankle-brachial index is stronger in poorly than in well controlled diabetes: Results from the Heinz Nixdorf Recall cohort study.
    Atherosclerosis. 2019;284:37-43.
    >> Share

    February 2019
  41. SUNDHOLM JKM, Litwin L, Rono K, Koivusalo SB, et al
    Maternal obesity and gestational diabetes: Impact on arterial wall layer thickness and stiffness in early childhood - RADIEL study six-year follow-up.
    Atherosclerosis. 2019 Feb 12. pii: S0021-9150(19)30064.
    >> Share

    January 2019
  42. LIU X, Li J, Liao J, Wang H, et al
    Gpihbp1 deficiency accelerates atherosclerosis and plaque instability in diabetic Ldlr(-/-) mice.
    Atherosclerosis. 2019;282:100-109.
    >> Share

    December 2018
  43. SAEED A, Sun W, Agarwala A, Virani SS, et al
    Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study.
    Atherosclerosis. 2018;282:52-56.
    >> Share

  44. WAKE M, Oh A, Onishi Y, Guelfucci F, et al
    Adherence and persistence to hyperlipidemia medications in patients with atherosclerotic cardiovascular disease and those with diabetes mellitus based on administrative claims data in Japan.
    Atherosclerosis. 2018;282:19-28.
    >> Share

  45. ZHAO Y, Evans MA, Allison MA, Bertoni AG, et al
    Multisite atherosclerosis in subjects with metabolic syndrome and diabetes and relation to cardiovascular events: The Multi-Ethnic Study of Atherosclerosis.
    Atherosclerosis. 2018 Dec 15. pii: S0021-9150(18)31525.
    >> Share

    November 2018
  46. BOJANIN D, Vekic J, Milenkovic T, Vukovic R, et al
    Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control.
    Atherosclerosis. 2018;280:14-20.
    >> Share

  47. GUO J, Nunley KA, Costacou T, Miller RG, et al
    Greater progression of coronary artery calcification is associated with clinically relevant cognitive impairment in type 1 diabetes.
    Atherosclerosis. 2018;280:58-65.
    >> Share

    October 2018
  48. SAELY CH, Schindewolf M, Zanolin D, Heinzle CF, et al
    Single and combined effects of peripheral artery disease and of type 2 diabetes mellitus on the risk of cardiovascular events: A prospective cohort study.
    Atherosclerosis. 2018;279:32-37.
    >> Share

    September 2018
  49. BARTER PJ, Cochran BJ, Rye KA
    CETP inhibition, statins and diabetes.
    Atherosclerosis. 2018;278:143-146.
    >> Share

    August 2018
  50. BYUN JK, Choi BG, Rha SW, Choi SY, et al
    Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention.
    Atherosclerosis. 2018;277:130-135.
    >> Share

  51. MA M, Hui J, Zhang QY, Zhu Y, et al
    Long non-coding RNA nuclear-enriched abundant transcript 1 inhibition blunts myocardial ischemia reperfusion injury via autophagic flux arrest and apoptosis in streptozotocin-induced diabetic rats.
    Atherosclerosis. 2018;277:113-122.
    >> Share

  52. MUNOZ-HERNANDEZ L, Ortiz-Bautista RJ, Brito-Cordova G, Lozano-Arvizu F, et al
    Cholesterol efflux capacity of large, small and total HDL particles is unaltered by atorvastatin in patients with type 2 diabetes.
    Atherosclerosis. 2018;277:72-79.
    >> Share

    July 2018
  53. TASKINEN MR, Del Prato S, Bujas-Bobanovic M, Louie MJ, et al
    Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial.
    Atherosclerosis. 2018;276:124-130.
    >> Share

  54. PALANCA A, Castelblanco E, Perpinan H, Betriu A, et al
    Prevalence and progression of subclinical atherosclerosis in patients with chronic kidney disease and diabetes.
    Atherosclerosis. 2018;276:50-57.
    >> Share

  55. PAN HC, Chou KM, Lee CC, Yang NI, et al
    Circulating Klotho levels can predict long-term macrovascular outcomes in type 2 diabetic patients.
    Atherosclerosis. 2018;276:83-90.
    >> Share

  56. HEIER M, Ofstad AP, Borja MS, Brunborg C, et al
    High-density lipoprotein function is associated with atherosclerotic burden and cardiovascular outcomes in type 2 diabetes.
    Atherosclerosis. 2018 Jul 6. pii: S0021-9150(18)31201.
    >> Share

    June 2018
  57. MIETTINEN HE, Rono K, Koivusalo SB, Eriksson JG, et al
    Effect of gestational diabetes mellitus on newborn cholesterol metabolism.
    Atherosclerosis. 2018;275:346-351.
    >> Share

    May 2018
  58. MANCINI GBJ, Boden WE, Brooks MM, Vlachos H, et al
    Impact of treatment strategies on outcomes in patients with stable coronary artery disease and type 2 diabetes mellitus according to presenting angina severity: A pooled analysis of three federally-funded randomized trials.
    Atherosclerosis. 2018 May 31. pii: S0021-9150(18)30179.
    >> Share

  59. SUNG KC, Lee MY, Kim YH, Huh JH, et al
    Obesity and incidence of diabetes: Effect of absence of metabolic syndrome, insulin resistance, inflammation and fatty liver.
    Atherosclerosis. 2018;275:50-57.
    >> Share

  60. COLOMBO M, Looker HC, Farran B, Agakov F, et al
    Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes.
    Atherosclerosis. 2018;274:182-190.
    >> Share

  61. RAGGI P
    Angina severity, therapeutic choices and outcome in patients with diabetes mellitus.
    Atherosclerosis. 2018 May 3. pii: S0021-9150(18)30223.
    >> Share

    April 2018
  62. WILCOX T, Newman JD, Maldonado TS, Rockman C, et al
    Peripheral vascular disease risk in diabetic individuals without coronary heart disease.
    Atherosclerosis. 2018 Apr 30. pii: S0021-9150(18)30211.
    >> Share

  63. MACEDONI M, Hovnik T, Plesnik E, Kotnik P, et al
    Metabolic control, ApoE genotypes, and dyslipidemia in children, adolescents and young adults with type 1 diabetes.
    Atherosclerosis. 2018;273:53-58.
    >> Share

    March 2018
  64. SUAREZ-ORTEGON MF, McLachlan S, Price AH, Fernandez-Balsells M, et al
    Decreased iron stores are associated with cardiovascular disease in patients with type 2 diabetes both cross-sectionally and longitudinally.
    Atherosclerosis. 2018;272:193-199.
    >> Share

  65. AL-SHAREA A, Murphy AJ, Huggins LA, Hu Y, et al
    SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr(-/-) type 1 diabetic mice.
    Atherosclerosis. 2018;271:166-176.
    >> Share

  66. SINIARSKI A, Haberka M, Mostowik M, Golebiowska-Wiatrak R, et al
    Treatment with omega-3 polyunsaturated fatty acids does not improve endothelial function in patients with type 2 diabetes and very high cardiovascular risk: A randomized, double-blind, placebo-controlled study (Omega-FMD).
    Atherosclerosis. 2018;271:148-155.
    >> Share

    February 2018
  67. RAGGI P
    Atherosclerosis imaging to refine cardiovascular risk assessment in diabetic patients: Computed tomography and positron emission tomography applications.
    Atherosclerosis. 2018;271:77-83.
    >> Share

    December 2017
  68. LIGHTELL DJ JR, Moss SC, Woods TC
    Upregulation of miR-221 and -222 in response to increased extracellular signal-regulated kinases 1/2 activity exacerbates neointimal hyperplasia in diabetes mellitus.
    Atherosclerosis. 2017;269:71-78.
    >> Share

  69. TORRES-PENA JD, Garcia-Rios A, Delgado-Casado N, Gomez-Luna P, et al
    Mediterranean diet improves endothelial function in patients with diabetes and prediabetes: A report from the CORDIOPREV study.
    Atherosclerosis. 2017;269:50-56.
    >> Share

    November 2017
  70. CHRISTODOULOU E, Kadoglou NPE, Stasinopoulou M, Konstandi OA, et al
    Crocus sativus L. aqueous extract reduces atherogenesis, increases atherosclerotic plaque stability and improves glucose control in diabetic atherosclerotic animals.
    Atherosclerosis. 2017 Nov 1. pii: S0021-9150(17)31370.
    >> Share

    October 2017
  71. GANJALI S, Dallinga-Thie GM, Simental-Mendia LE, Banach M, et al
    HDL functionality in type 1 diabetes.
    Atherosclerosis. 2017;267:99-109.
    >> Share

    September 2017
  72. MARCADENTI A, Fuchs FD, Moreira LB, Gus M, et al
    Adiposity phenotypes are associated with type-2 diabetes: LAP index, body adiposity index, and neck circumference.
    Atherosclerosis. 2017;266:145-150.
    >> Share

    August 2017
  73. SCHMIDT N, Schmidt B, Dressel A, Gergei I, et al
    Familial hypercholesterolemia in primary care in Germany. Diabetes and cardiovascular risk evaluation: Targets and Essential Data for Commitment of Treatment (DETECT) study.
    Atherosclerosis. 2017;266:24-30.
    >> Share

  74. CAMARGO GARCIA A, Garcia-Carpintero S, Lopez-Moreno J, Jimenez-Lucena R, et al
    Postprandial endotoxemia may influence the type 2 diabetes mellitus development.
    Atherosclerosis. 2017;263:e98.
    >> Share

  75. STECHOVA K, Sklenarova J, Kratzerova T, Filipp D, et al
    Association between immune and lipid factors in women with diabetes type 1.
    Atherosclerosis. 2017;263:e97-e98.
    >> Share

  76. EL KHOURY P, Roussel R, Fumeron F, Velho G, et al
    Plasma PCSK9 and cardiovascular events in type 2 diabetes.
    Atherosclerosis. 2017;263:e81.
    >> Share

  77. WITKOWSKI M, Weithauser A, Tabaraie T, Steffens D, et al
    Endothelial micrornas epigenetically control vascular inflammation and thrombogenicity in diabetes.
    Atherosclerosis. 2017;263:e76.
    >> Share

  78. SUN Y, Kopp S, Gali CC, Zandl M, et al
    Gestational diabetes mellitus modulates cholesterol metabolism in human fetoplacental endothelial cells.
    Atherosclerosis. 2017;263:e74-e75.
    >> Share

  79. WALUS-MIARKA M, Idzior-Walus B, Trojak A, Kapusta M, et al
    Pentraxin 3 concentration in patients with type 2 diabetes mellitus and NAFLD.
    Atherosclerosis. 2017;263:e54.
    >> Share

  80. PITHOVA P, Pitha J, Stechova K, Kvapil M, et al
    Preclinical atherosclerosis is associated with insulin resistance in type 1 diabetes women.
    Atherosclerosis. 2017;263:e54.
    >> Share

  81. IHM SH, Lee KY, Kim JJ, Hwang BH, et al
    CT Angiography-imaged coronary artery stenosis provides better risk prediction than traditional risk factors in asymptomatic diabetic individuals: A long-term study of clinical outcomes.
    Atherosclerosis. 2017;263:e53.
    >> Share

  82. ILYAS Z, Al-Ghamdi J, Nguan-Soon T, Kiss-Toth E, et al
    Tribbles-3, a regulator of metabolic syndromes and type 2 diabetes.
    Atherosclerosis. 2017;263:e50.
    >> Share

  83. CAVALCANTE MARANHAO R, Franca Marques A, Guido MC, Rufo Tavares E, et al
    Effects of treatment with methotrexate associated to lipid nanoparticles on diabetic cardiomyopathy in rats.
    Atherosclerosis. 2017;263:e48.
    >> Share

  84. STOJIC I, Tepic S, Petkovic A, Srejovic I, et al
    Time dependent effects of hbot on redox status in diabetic patients.
    Atherosclerosis. 2017;263:e276.
    >> Share

  85. MANEA V, Pop C, Pop L
    Correlations of dipper profiles in diabetic patients with hypertension: the importance of ambulatory blood pressure monitoring/24 hours.
    Atherosclerosis. 2017;263:e276.
    >> Share

  86. KYRIAZIS I, Sgouros K, Stefani D, Vallianou K, et al
    The effect of the presence and the level of dyslipidemia control on diabetic patients with first acute ischemic stroke.
    Atherosclerosis. 2017;263:e275-e276.
    >> Share

  87. PITHA J, Pithova P, Roztocil K, Urbaniec K, et al
    Oliva-roztocil index, specific parameter of vascular damage in women suffering from diabetes mellitus.
    Atherosclerosis. 2017;263:e275.
    >> Share

  88. KUMAR N, Khanna RK
    Anti-diabetic effect of trigonella foenum greacum seed acetone fraction in a type 2 diabetes model of rats.
    Atherosclerosis. 2017;263:e273.
    >> Share

  89. BAUDIN B, Nekaies Y, Baudin B, Kelbousi S, et al
    Association of apolipoproteins plasma levels with PCSK9 in type 2 diabetes mellitus.
    Atherosclerosis. 2017;263:e273-e274.
    >> Share

  90. RAJPUT S, Sinha S
    Modulation of the coexistence of diabetes and hypothyroidism on body weight gain, leptin and various metabolic aspects in wistar rats.
    Atherosclerosis. 2017;263:e272.
    >> Share

  91. DIOSZEGI A, Vass M, Nemeth N, Sogor V, et al
    Rheopheresis treatment of diabetic foot syndrome.
    Atherosclerosis. 2017;263:e272.
    >> Share

  92. NANASY-VASS M, Dioszegi A, Flasko A, Mechler F, et al
    Study of microcirculatory impairment in type 2 diabetic patients with symptoms of peripherial neuropathy.
    Atherosclerosis. 2017;263:e272-e273.
    >> Share

  93. SHALAEVA E, Janabaev B, Bobabekov A, Kasimov U, et al
    Coronary computed tomographic angiography and coronary artery calcium score in patients with type 2 diabetes undergoing trans-femoral amputation in 2013 in different clinical groups.
    Atherosclerosis. 2017;263:e271-e272.
    >> Share

  94. ENA J, Perez S, Alvarez CE, Valls V, et al
    Triglyceride to high density lipoprotein cholesterol ratio, total cholesterol to high density lipoprotein cholesterol ratio and low ankle brachial index in patients with diabetes.
    Atherosclerosis. 2017;263:e270.
    >> Share

  95. ENA J, Perez S, Argente CR, Lozano T, et al
    Systolic blood pressure difference between arms and peripheral arterial disease in patients with diabetes mellitus.
    Atherosclerosis. 2017;263:e270-e271.
    >> Share

  96. ZIVKOVIC V, Vranic A, Simovic S, Ristic P, et al
    The acute effects of different spironolactone doses on cardiac function in streptozotocine-induced diabetic rats.
    Atherosclerosis. 2017;263:e268-e270.
    >> Share

  97. DUARTE JS, Bello C, Ferreira R, Limbert C, et al
    Atherogenic dislipidemia in patients with type 2 diabetes linked to microvascular complications and heart disease.
    Atherosclerosis. 2017;263:e265.
    >> Share

  98. ZHILINA S, Miramontes Gonzalez JP, Laso Guzman FJ
    Familial hypercholesterolemia and the diabetogenic effect of statins.
    Atherosclerosis. 2017;263:e264.
    >> Share

  99. BENEDI MVM, Calahorra SP, Sanz AMB, Baila Rueda L, et al
    A randomized, open-label study to investigate the effect of a high protein diet compared to a normoprotein diet on hydrocarbon metabolism in patients with diabetes or prediabetes and obesity.
    Atherosclerosis. 2017;263:e263.
    >> Share

  100. NIKOLOVA A, Milanova M, Stoyanov K, Yankov G, et al
    Risk assessment for diabetes mellitus type 2 in women.
    Atherosclerosis. 2017;263:e263-e264.
    >> Share

  101. SZTANEK F, Seres I, Lorincz H, Molnar A, et al
    Effect of alpha-lipoic acid supplementation on oxidative stress markers and antioxidative defense in patients with diabetic neuropathy.
    Atherosclerosis. 2017;263:e263.
    >> Share

  102. CASULA M, Mozzanica F, Scotti L, Tragni E, et al
    Statin use and risk of new-onset diabetes: a meta-analysis of observational studies.
    Atherosclerosis. 2017;263:e262-e263.
    >> Share

  103. DOULAMIS I, Tzani A, Konstantopoulos P, Antoranz A, et al
    Targeted proteomics identification of biomarkers for diabetes mellitus in patients with cardiovascular disease.
    Atherosclerosis. 2017;263:e261.
    >> Share

  104. PARAGH G, Lorincz H, Somodi S, Varga VE, et al
    Serum afamin level is strongly associated to the components of metabolic syndrome in non-diabetic obese patients.
    Atherosclerosis. 2017;263:e261.
    >> Share

  105. OVSYANNIKOVA A, Rymar O, Shaksthneider E, Ragino Y, et al
    The prevalence of dyslipidemia in young patients with diabetes mellitus.
    Atherosclerosis. 2017;263:e260-e261.
    >> Share

  106. OVSYANNIKOVA A, Rymar O, Shaksthneider E, Voevoda M, et al
    Clinical case: The development of atherosclerosis in a patient 28 years old with 12 mody diabetes.
    Atherosclerosis. 2017;263:e260.
    >> Share

  107. BARKAS F, Elisaf M, Liberopoulos E, Liamis G, et al
    Metabolic markers to predict incident diabetes in statin-treated individuals.
    Atherosclerosis. 2017;263:e259.
    >> Share

  108. SHAKHTSHNEIDER E, Ovsyannikova A, Ivanoshchuk D, Rymar O, et al
    The spectrum of mutations in the CEL gene in early onset diabetes patients.
    Atherosclerosis. 2017;263:e259-e260.
    >> Share

  109. GARCIA-DONAIRE JA, Franch-Nadal J, Rodriguez-Fortunez P, Labrador-Barba E, et al
    The importance of the training as an integral part of caring for the diabetic patient. FORMA2 study: Differences between urban and rural work area.
    Atherosclerosis. 2017;263:e258.
    >> Share

  110. SHALIMOVA A, Bilovol O, Bobronnikova L
    Severity of cardiovascular remodeling in comorbidity of essential hypertension and type 2 diabetes depending on genetic polymorphism of AGTR1 and IRS-1.
    Atherosclerosis. 2017;263:e258.
    >> Share

  111. HAN Y, Jang YN, Lee YJ, Kim HM, et al
    Fimasartan nomalizes carbohydrate metabolism through AMPK pathway in diabetic condition.
    Atherosclerosis. 2017;263:e258-e259.
    >> Share

  112. VONBANK A, Zanolin D, Leiherer A, Rein P, et al
    The power of thyroid stimulating hormone to predict cardiovascular mortality in non-obese patients is significantly modulated by type 2 diabetes.
    Atherosclerosis. 2017;263:e256.
    >> Share

  113. SAELY C, Vonbank A, Zanolin D, Leiherer A, et al
    Single and joint effects of obesity and of the metabolic syndrome on the development of diabetes in patients with coronary atherosclerosis.
    Atherosclerosis. 2017;263:e256.
    >> Share

  114. SAELY C, Rein P, Leiherer A, Vonbank A, et al
    Remnant cholesterol predicts the development of type 2 diabetes mellitus in patients with established coronary artery disease.
    Atherosclerosis. 2017;263:e256.
    >> Share

  115. SAELY C, Zanolin D, Rein P, Leiherer A, et al
    Concordance of glucose-based and of HbA1c-based diagnoses of diabetes in patients with peripheral arterial disease-a comparison between men and women.
    Atherosclerosis. 2017;263:e255.
    >> Share

  116. SAELY C, Zanolin D, Vonbank A, Leiherer A, et al
    Non-alcoholic fatty liver disease strongly predicts incident diabetes in patients with coronary artery disease.
    Atherosclerosis. 2017;263:e255-e256.
    >> Share

  117. DEMIKHOVA N, Chernatska O, Smiianova O, Vynnychenko L, et al
    The correlation between polimorphism of CYP7a1 gene and glycated hemoglobin in hypertensive patients with type 2 diabetes mellitus.
    Atherosclerosis. 2017;263:e254.
    >> Share

  118. KIM BJ, Han JM, Do JH, Kim BS, et al
    Sex-specific relationship between cotinine-verified second-hand smoke exposure and diabetes in 85,697 never-smokers.
    Atherosclerosis. 2017;263:e254.
    >> Share

  119. EISENGA M, Zelle D, Sloan J, Gaillard C, et al
    High serum PCSK9 is associated with increased risk of new-onset diabetes after transplantation in renal transplant recipients.
    Atherosclerosis. 2017;263:e254-e255.
    >> Share

    Effect of canagliflozin on visceral fat area and heart rate in patients with type 2 diabetes mellitus.
    Atherosclerosis. 2017;263:e252.
    >> Share

  121. FULOP P, Seres I, Lorincz H, Somodi S, et al
    Lipocalin 2 may be a potential biomarker of atherosclerotic complications in obese non-diabetic individuals.
    Atherosclerosis. 2017;263:e250.
    >> Share

  122. SZENTPETERI A, Lorincz H, Somodi S, Varga VE, et al
    Human obestatin level and its correlations with metabolic syndrome components in non-diabetic obese patients.
    Atherosclerosis. 2017;263:e250.
    >> Share

  123. KARASEK D, Gajdova J, Kubickova V, Krystynik O, et al
    Selected adipokines in patients with type 2 diabetes: Relationship to soluble markers of endothelial dysfunction-a pilot study.
    Atherosclerosis. 2017;263:e249.
    >> Share

  124. ASKRI I, Kelbousi S, Sakly M, Attia N, et al
    Atorvastatin effect on phospholipid profile and distribution between lipoprotein fractions in type 2 diabetic patients with and without CAD.
    Atherosclerosis. 2017;263:e246.
    >> Share

  125. YASUDA H, Fujiwara A, Komiya S, Haze T, et al
    Effects of rosuvastatin add-on treatment on hyperlipidemia in type 2 diabetic patients with chronic kidney disease receiving ethyl icosapentate.
    Atherosclerosis. 2017;263:e241-e242.
    >> Share

  126. BATURINA O, Mironova O
    Clinical case of hyperlipidemia type IV in a man with diabetes, myocardial infarction and stroke.
    Atherosclerosis. 2017;263:e227-e228.
    >> Share

  127. MAGLAPHERIDZE Z, Tabukashvili R, Kapetivadze V, Tchaava K, et al
    Treatment of dyslipidemia in diabetic type 2 patients with hypertension.
    Atherosclerosis. 2017;263:e217.
    >> Share

  128. MARANHAO RC, Tavoni TM, Laverdy Neto OG, Sprandel MDCO, et al
    Differences in lipid transfers to HDL between patients with coronary arterial disease with or without type 2 diabetes mellitus.
    Atherosclerosis. 2017;263:e217.
    >> Share

  129. ARAGONA CO, Cairo V, Scuruchi M, Giunta L, et al
    Evaluation of Lp(a) and insulin during pregnancy in not diabetic women. Preliminary data.
    Atherosclerosis. 2017;263:e208.
    >> Share

  130. WALUS-MIARKA M, Trojak A, Kapusta M, Idzior-Walus B, et al
    Pentraxin 3 concentration is positively associated with apo C3 and abdominal obesity in men with type 2 diabetes.
    Atherosclerosis. 2017;263:e207.
    >> Share

  131. VASILKOVA V, Mokhort T, Naumenko E, Zmailik M, et al
    Association between systolic dysfunction and inflammation in diabetic patients with chronic kidney disease.
    Atherosclerosis. 2017;263:e191.
    >> Share

  132. LAKHOUA Y, Ben Nacef I, Bouzid K, M'Chrirgui N, et al
    Prevalence of diabetes and frequency of cardiovascular risk factors in paramedical and administrative staff of Charles Nicolle hospital.
    Atherosclerosis. 2017;263:e180-e181.
    >> Share

  133. VONBANK A, Saely C, Rein P, Leiherer A, et al
    The visceral adiposity index predicts cardiovascular events both in coronary artery disease patients with and in coronary artery disease patients without diabetes.
    Atherosclerosis. 2017;263:e172-e173.
    >> Share

  134. VIKULOVA O, Bolotskaya L, Bessmertnaya E, Artemova E, et al
    Frequency of diabetic complications and HbA1C level by active screening and diabetes registry data: Comparative study.
    Atherosclerosis. 2017;263:e171.
    >> Share

  135. KONSTANTOPOULOS P, Tzani A, Doulamis IP, Korou ML, et al
    Anti-inflammatory, hypolipidemic and hepatoprotective properies of CMG in an experimental model of diabetes.
    Atherosclerosis. 2017;263:e166-e167.
    >> Share

  136. REVNIC CR, Revnic F, Pena C, Nica AS, et al
    The role of physical training on neuroendocrine axis, physiology and metabolism in elderly with/without diabetes.
    Atherosclerosis. 2017;263:e161.
    >> Share

  137. KUMAR S, Sharma V
    Hypertension, obesity, diabetes, and heart failure-free survival: The cardiovascular disease lifetime risk pooling project in New Delhi, India.
    Atherosclerosis. 2017;263:e159.
    >> Share

  138. NOVAKOVIC R, Cirovic S, Markovic-Lipkovski J, Rajkovic J, et al
    Effect of polyphenol resveratrol on the isolated renal artery of normal and diabetic rats.
    Atherosclerosis. 2017;263:e157.
    >> Share

  139. STOJANOVIC M, Radenkovic M
    Clarification of serotonin-induced effects in peripheral artery disease via the rat femoral artery response in models of diabetes and vascular occlusion.
    Atherosclerosis. 2017;263:e133-e134.
    >> Share

  140. RAJKOVIC J, Peric M, Stanisic J, Rakocevic J, et al
    Involvement of ATP-sensitive potassium channels in effect of pinacidil on saphenous vein obtained from the patients with and without type 2 diabetes mellitus.
    Atherosclerosis. 2017;263:e131.
    >> Share

  141. NIKOLOV A, Tsinlikov I, Tsinlikova I, Nicoloff G, et al
    Levels of anti-elastin IgA antibodies are associated with high risk of atherosclerosis in diabetics with essential hypertension.
    Atherosclerosis. 2017;263:e124-e125.
    >> Share

  142. MELNIKOV I, Gabbasov Z, Kozlov S, Byazrova S, et al
    Assessment of novel biomarkers for restenosis occurrence after drug-eluting stent implantation in patients with stable coronary artery disease and type 2 diabetes mellitus.
    Atherosclerosis. 2017;263:e121-e122.
    >> Share

  143. VIRTA J, Silvola J, Hellberg S, Stahle M, et al
    Effects of linagliptin intervention on atherosclerotic plaque inflammation and 18F-FDG uptake in a mouse model of type 2 diabetes.
    Atherosclerosis. 2017;263:e119-e120.
    >> Share

  144. PETELINA T, Musikhina N, Gapon L, Emeneva I, et al
    Features of atherogenic lipid profile and inflammatory markers in patients with stable angina and type 2 diabetes mellitus.
    Atherosclerosis. 2017;263:e118.
    >> Share

  145. KULIKOWSKI E, Calosing C, Tsujikawa L, Wasiak S, et al
    Apabetalone (RVX-208) may lower CVD events in diabetes mellitus by affecting complement pathway and microbiome activity.
    Atherosclerosis. 2017;263:e113.
    >> Share

  146. POVLSEN GK, Langhi C, Skytte Olsen G
    Regulation of hepatic LDL-receptor and PCSK9 expression by insulin in diabetic mice and in vitro in hepatocyte models.
    Atherosclerosis. 2017;263:e102.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016